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Background: The serine-threonine kinase AKT1 plays essential roles during normal mammary gland development
as well as the initiation and progression of breast cancer. AKT1 is generally considered a ubiquitously expressed
gene, and its persistent activation is transcriptionally controlled by regulatory elements characteristic of housekeeping
gene promoters. We recently identified a novel Akt1 transcript in mice (Akt1m), which is induced by growth factors and
their signal transducers of transcription from a previously unknown promoter. The purpose of this study was to examine
whether normal and neoplastic human breast epithelial cells express an orthologous AKT1m transcript and whether its
expression is deregulated in cancer cells.
Methods: Initial sequence analyses were performed using the UCSC Genome Browser and GenBank to assess the potential
occurrence of an AKT1m transcript variant in human cells and to identify conserved promoter sequences that are orthologous
to the murine Akt1m. Quantitative RT-PCR was used to determine the transcriptional activation of AKT1m in mouse mammary
tumors as well as 41 normal and neoplastic human breast epithelial cell lines and selected primary breast cancers.
Results:We identified four new AKT1 transcript variants in human breast cancer cells that are orthologous to the murine
Akt1m and that encode the full-length kinase. These transcripts originate from an alternative promoter that is conserved
between humans and mice. Akt1m is upregulated in the majority of luminal-type and basal-type mammary cancers in four
different genetically engineered mouse models. Similarly, a subset of human breast cancer cell lines and primary breast cancers
exhibited a higher expression of orthologous AKT1m transcripts.
Conclusions: The existence of an alternative promoter that drives the expression of the unique AKT1m transcript may provide
a mechanism by which the levels of AKT1 can be temporally and spatially regulated at particular physiological states, such as
cancer, where a heightened activity of this kinase is required.
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The PI3-kinase/AKT pathway is one of the most fre-
quently altered signaling cascades in a large variety of
human cancers. The deregulated expression and activa-
tion of signal transducers in this pathway can occur
through various mechanisms such as hereditary or spor-
adic mutations (e.g., PIK3CA, PIK3R1, AKT1/3, PDK1),* Correspondence: kuwagner@unmc.edu
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unless otherwise stated.amplification or transcriptional upregulation (e.g., PIK3CA,
AKT1/3), transcriptional repression or deletion of negative
regulators such as PTEN, as well as increased expression
or activity of growth factors and their corresponding re-
ceptors that signal through PI3K and AKT (e.g., IGF1,
HER2) [1]. This signaling cascade therefore has received
considerable attention in drug targeting, but balancing
efficacy with safety (i.e., the therapeutic index) has
proved to be a considerable hurdle to overcome [2]. Ef-
forts directed at downregulating this pathway have fo-
cused largely on inhibiting protein function through
small molecule inhibitors rather than on investigatingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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naling through transcriptional downregulation.
Similar to the PI3 kinase, AKT1 is generally considered
a ubiquitously expressed gene, and sequencing studies
performed more than 20 years ago revealed that the
AKT1 locus contains GC-rich regulatory elements char-
acteristic of housekeeping gene promoters [3]. We re-
cently identified a novel Ak11 transcript (Akt1m) that is
controlled by a previously unknown mammary-specific
promoter in mice [4]. The new transcript includes a
completely different 3′ untranslated exon and encodes
the full-length AKT1 protein with the ATG translation
initiation codon in exon 2. Expression of Akt1m mRNA
from this promoter is controlled by prolactin and JAK2/
STAT5 signaling and is upregulated more than 500-fold
during lactation compared to the virgin mammary gland,
contributing to more than a 7-fold increase in total Akt1
mRNA. The identification of this growth factor-induced
promoter in mice provides a mechanism by which the
levels of AKT1 can be temporally and spatially regulated
at particular physiological states where heightened AKT1
activity is required (e.g., during lactation when metabolic
needs are high).
It is an established fact that neoplastic cells hijack nor-
mal developmental pathways to support their unique
metabolic requirements and to enhance cell prolifera-
tion, survival, and migration [5]. Using human cell lines
and genetically engineered mice that are deficient in
AKT1, it has been demonstrated that signaling through
this serine-threonine kinase is critical for the initiation
and progression of breast cancer [6-8]. Since growth fac-
tors such as prolactin and their downstream effectors
play key roles in mammary tumorigenesis [9,10], it is
feasible to hypothesize that cancer cells aberrantly acti-
vate the newly identified promoter to upregulate the
transcriptional expression of Akt1. Given the histological
and functional similarities of the mammary epithelium
as well as the requirement of identical molecular path-
ways for the development of mammary glands in
humans and mice, we postulated that the human gen-
ome might also contain an orthologous promoter that
contributes to the transcriptional regulation of the AKT1
gene. If this is the case, these orthologous regulatory ele-
ments might also be atypically activated in human breast
cancers. This line of investigation might provide insight
into the development of alternative strategies to modu-
late the expression of AKT1 in neoplastic cells.
Methods
Genetically modified mouse strains
The generation and analysis of the MMTV-Cre-based
BRCA1 conditional knockout model (Brca1−/−) was de-
scribed previously [11,12]. Mutant PtenG129E mice [13]
were kindly provided by Dr. Gustavo Leone (The OhioState University). MMTV-neu transgenic mice [14] were
obtained from the Jackson Laboratory. Transgenic lines
that overexpress PRL in the mammary gland under the
control of the neu-related lipocalin promoter [NRL-PRL]
were published previously [15]. Mammary tumors that
arose spontaneously in aging females of these genetically
engineered mouse strains were flash frozen and stored
in liquid nitrogen. All animals used in this study were
treated humanely and in accordance with institutional
guidelines and federal regulations. This study was car-
ried out in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Ani-
mals of the National Institutes of Health. The protocol
was approved by the Institutional Animal Care and Use
Committee of the University of Nebraska Medical
Center (IACUC#: 09-104-01, 03-104-01, and 12-008-03).
Human breast cancer cell lines and tissue specimens
A panel of 43 human breast cancer cell lines was ob-
tained from the American Type Culture Collection
(ATCC) with financial support from the Integrative Can-
cer Biology Program at the National Cancer Institute
(NCI). Forty-one of these cell lines were expanded and
maintained using media and supplements recommended
by ATCC. Deidentified flash-frozen human specimens
representing normal tissues of the breast, lung, liver,
pancreas, and stomach as well as nine human breast
cancers representing the three major breast cancer sub-
types (ERα-positive, ERBB2/HER2-positive, and triple-
negative) were obtained under institutional guidelines
from the tissue bank at the University of Nebraska Med-
ical Center (UNMC).
mRNA expression analyses using quantitative
real-time PCR
Total RNA was extracted from flash-frozen tissues and
cell pellets using standard guanidinium thiocynate-
phenol-chloroform extraction or the RNeasy Mini Kit
(Qiagen). The Super-Script II kit from Invitrogen with
oligo-dT primers was used to perform the first-strand syn-
thesis according to the manufacture’s protocol. Quantita-
tive real-time PCR (qPCR) was performed using iQ SYBR
green Supermix (Bio-Rad, Hercules, CA) and mRNA-
specific forward primers for the mouse Akt1m (5′-GTC
GCC ACC TGC TTG CTG AGG-3′) and the human
orthologous AKT1m (5′-CCT TCC TCG AGT CTG
GCC TG-3′). The reverse primers bind within the second
coding exon of the mouse (5′-GGA CTC TCG CTG ATC
CAC ATC C-3′) and the human AKT1 (5′-GTA GCC
AAT GAA GGT GCC ATC-3′) cDNAs, respectively. The
qPCR reactions were carried out in triplicate in a CFX96
Real-Time PCR Detection System (Bio-Rad). The expres-
sion values obtained were normalized against Gapdh as
described previously [4].
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Detailed experimental procedures for immunoprecipita-
tion (IP) and western blot analysis were described else-
where [16]. The following antibodies were used for
immunoblotting: α-β-ACTIN (I-19) from Santa Cruz
Biotechnology; α-pAKT (Ser473) (9271) from Cell Sig-
naling and α-AKT1 (1081–1) from Epitomics.
In Silico analysis
In silico genomic analyses of the human AKT1 locus
were performed using GenBank (http://www.ncbi.nlm.
nih.gov/genbank/) and the UCSC Genome Browser
(http://genome.ucsc.edu) [17,18]. The comprehensive
analysis of the AKT1 locus included assessing transcript
variants, promoter genetic elements, interspecies genetic
conservation, and reported ChIP data. The sequences
of the mouse and novel human AKT1m cDNAs were
submitted to GenBank (accession numbers KF836746
through KF836750).
Statistical analysis
All graphic illustrations and statistics were performed
with Prism 5 software (GraphPad Software, Inc., La Jolla,
CA). Data are expressed as mean ± SD unless otherwise
indicated and were compared using an unpaired Student
t test. A P of less than .05 was considered significant.
Results
Akt1m is expressed and upregulated in the majority of
mouse mammary tumors
We performed quantitative RT-PCR on a panel of mam-
mary tumors from diverse genetic cancer models to as-
sess whether the Akt1m mRNA transcript is aberrantly
expressed during mammary tumorigenesis in genetically
engineered mice. Specifically, we examined the expression
of Akt1m in primary cancers from BRCA1 conditional
knockout mice (Brca1−/−), PtenG129E mutant females as well
as transgenic mice that overexpress ERBB2 (MMTV-neu)
and prolactin (NRL-PRL). These models represent the
major breast cancer subtypes found in humans, includ-
ing triple-negative, basal-type lesions lacking BRCA1,
HER2/ERBB2-positive tumors, as well as ERα-negative
and ERα-positive, luminal-type cancers that originate in
mice expressing mutant PTEN and prolactin in the
mammary gland. The levels of expression in these neo-
plasms were matched to normal mammary gland tissues
from virgin, lactating, involuting, and nonpregnant mul-
tiparous females. Consistent with our previous findings,
Akt1m was upregulated approximately 1000-fold during
lactation as compared to the virgin state. Its expression
swiftly declined within two days following the weaning
of the offspring and prior to postlactational remodeling
of the mammary gland (Figure 1A). There was a small
but noticeable increase in the expression of Akt1m inthe multiparous mammary tissue. This is likely due to the
emergence and expansion of a unique epithelial subtype,
which we identified using genetic cell-fate mapping
and named pregnancy-induced mammary epithelial
cells (PI-MECs) [19,20]. These cells are prolactin re-
sponsive and located at the terminal ends of the ductal
tree. They serve as alveolar progenitors during succes-
sive pregnancies, and we have previously demonstrated
that they are the cells of origin for many MMTV-neu-
induced mammary tumors [21]. In support of this no-
tion, all mammary tumors from MMTV-neu transgenic
females exhibited an elevated expression of the unique
Akt1m transcript (Figure 1A). However, the vast majority
of primary mammary cancers in all cancer models exhib-
ited a significant increase in the expression of Akt1m re-
gardless of the cellular subtypes that gave rise to luminal-
or basal-type mammary tumors. PtenG129E mutant mice
were maintained as nulliparous females. Based on the sig-
nificantly elevated expression of Akt1m in these tumors, it
is evident that a full-term pregnancy and gestation cycle
seems not to be a prerequisite for the upregulation of the
unique AKT1 transcript in neoplastic mammary epithelial
cells. As expected, the total levels of the AKT1 protein are
elevated in all mammary tumor subtypes, but the activa-
tion of this kinase varies significantly and is highest in tu-
mors with a known hyperactivation of the PI3 kinase in
response to ERBB2 overexpression or loss-of-function of
PTEN (Figure 1B). Efforts to elucidate the specific contri-
bution of the Akt1m to the total pool of Akt1 mRNA tran-
scripts using qRT-PCR failed due to the high GC-rich
content of the untranslated 5′exon following the basal
promoter.
The human genome contains a DNA sequence that is
orthologous to the murine Akt1m and that gives rise to
several new transcript variants encoding full-length AKT1
In an effort to identify the human Akt1m ortholog, we
performed an in silico analysis of the genomic
organization of the human AKT1 gene and transcripts
using the UCSC Genome Browser (Figure 2A). Four of
the five AKT1 gene transcripts that were listed resem-
bled the three known sequences that were present in
GenBank (Figure 2B). Interestingly, the fifth transcript
arose from an untranslated exon that did not resemble
any of the known GenBank entries and, furthermore,
was located at a similar position relative to the ATG
start site as the most 5′ murine Akt1m exon (Figure 2A,
arrow). A comparison of the sequences of this particular
exon with the mouse Akt1m DNA revealed they were, in
fact, orthologous to one another and exhibit 40% sequence
similarity within their overlapping region (Figure 2C).
Based on the human sequence of the orthologous Akt1m,
we designed a forward primer that binds specifically to
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Figure 1 The Akt1m transcript is upregulated during lactation and in mouse mammary tumors. (A) Quantitative real-time RT-PCR analysis
to assess the relative transcriptional activation of the Akt1m transcript at various stages of normal mammary gland development (nulliparous/virgin,
lactation, involution, and non-pregnant multiparous) as well as 12 mammary tumors from Brca1 conditional knockout mice (MMTV-Cre Brca1fl/fl, tumors
1–3), a model for Cowden Syndrome (PtenG129E, tumors 4–6), and transgenic females expressing wildtype ErbB2 (MMTV-neu, tumors 7–9) or prolactin
(NRL-PRL, tumors 10–12). Each sample was examined in triplicate and normalized to Gapdh expression. The relative expression levels of Akt1m were
compared to the virgin control female, and statistical analysis was performed for each sample relative to the virgin control; t test, *P < 0.05, **P < 0.01.
(B)Western blot analysis to determine the levels of phosphorylated AKT1 (pAKT, Ser473) and total AKT1 in selected mammary tumors (corresponding
to tumors 1, 4, 7, and 10 in panel A) in comparison to a normal mammary gland of a multiparous female (control). Beta-actin (ACTB) was used as a
loading control.
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these primers would allow detection of any AKT1
mRNA transcripts in human cells that include this
novel exon (Figure 3A). In contrast to the murine
Akt1m exon, which produced only a single transcript
in normal and neoplastic mammary epithelial cells, the
PCR amplification of the human AKT1m produced
multiple bands of varying sizes in T47-D human breast
cancer cells (Figure 3B). The four strongest bands, de-
noted ‘Transcript Variants 1-4′, were gel purified, cloned,
and sequenced. The sequence analysis confirmed thatthese novel AKT1 transcripts contained the orthologous
AKT1m exon depicted on the UCSC Genome Browser.
Specifically, the AKT1m transcript that we identified
using in silico analysis represented the transcript variant
4 (Figure 3C). Additionally, we cloned three new mRNA
variants consisting of the same initial 5′ untranslated
exon or a shortened version of the exon in the case of
transcript variant 2. These longer transcript variants
spliced into a second untranslated exon in front of the
first coding exon containing the ATG start site of the
full-length AKT1. Only the second exon is also shared


















Figure 2 Analysis of the human AKT1 locus and known transcripts to identify a sequence that is orthologous to the mouse Akt1m. (A)
Diagram of the human AKT1 promoter region with transcriptional start sites and the location of 5′ untranslated exons of five currently known
AKT1 transcripts using the UCSC Genome Browser. The red arrow indicates an exon that is not associated with any of the known transcripts in
GenBank. (B) Graphical illustration of all transcript variants of the human AKT1 that are present in GenBank. (C) Genomic sequence comparison of
the previously identified murine Akt1m exon with a putative human AKT1m ortholog according to the UCSC Genome Browser. Conserved
nucleotides are highlighted in yellow (40% sequence similarity).
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promoter (Figure 2B, middle). Collectively, the results
from the cloning and sequencing analysis of novel Akt1
mRNA variants reveal that the transcriptional activation
of this gene locus is more complex than previously
thought. Results from our own 5′RACE experiments [4]
and the analysis of all published sequences in GenBank
showed that the Akt1m non-coding exon was neverincluded in any of the mRNAs that originated from the
basal promoter. All previously and newly identified
transcripts utilize the same first coding exon containing
the ATG translation initiation codon and splice cor-
rectly into the following coding exons. It is therefore
evident that, like in mice, the full-length AKT1 kinase is
encoded by messenger RNAs from at least two distinct
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Figure 3 Cloning of four novel human AKT1 transcripts that are orthologous to the mouse Akt1m mRNA. (A) Schematic outline of the 5′
region of the human AKT1 gene with the two currently known untranslated exons (1, 2) and the location of a novel AKT1m exon according to
sequence comparison between the mouse and human genome. Arrows indicate the forward primer within AKT1m and the reverse primer in the
second coding exon (i.e., exon 4) that were used to clone novel mRNA variants that originate from an alternative genomic region. (B) PCR
amplicons of cDNAs from human T47-D breast cancer cells that contain the novel AKT1m exon. The four strongest bands were cloned and the
presence of the AKT1m exon was confirmed by sequencing. The sizes of the sequenced amplicons are shown in parentheses. (C) Graphic illustration
of the four new human AKT1m transcript variants that originate from a previously unidentified exon. Note that all of these transcripts splice into the
first coding exon, suggesting that all new transcripts encode the full-length AKT1 kinase.
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the AKT1m exon serves as a second promoter within the
AKT1 locus
Using the UCSC Genome Browser, we performed an-
other in silico analysis to identify regions of high similar-
ity between the human and mouse sequences preceding
the Akt1m exon. The presence of conserved sequences
might indicate the existence of a unique promoter thatdrives the expression of the alternative Akt1 mRNA en-
coding AKT1. This analysis revealed a DNA sequence of
158 bps in length that exhibits a 69% conservation be-
tween mouse and human beginning approximately 60 bps
upstream of Akt1m (Figure 4). Only 31% of the nucleo-
tides are similar in the sequence preceding the conserved
region, and the DNA exhibits merely 14% conservation








Figure 4 Identification of a conserved putative promoter sequence immediately upstream of the novel human and murine AKT1m
exon. The black bar within the graphic illustrations of the 5′ regions of the human and mouse AKT1 loci represents a highly conserved genomic
region of 158 bps in length. This region is located approximately 60 and 90 bps upstream of the human and mouse AKT1m exon, respectively.
The sequences exhibited a 69% conservation (bases highlighted in yellow).
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GAA [22]] downstream of exon 1 that we identified and
verified using ChIP analysis in mouse tissues is missing in
the human genome, suggesting that prolactin signaling
may not be directly involved in the transcriptional regula-
tion of the expression of AKT1m in humans. However, the
existence of a highly conserved region in close proximity
of the transcriptional start site of Akt1m is suggestive of a
putative promoter, and a subsequent analysis performed
using the Transcription Element Search System (TESS,
University of Pennsylvania) revealed multiple conserved
binding sites for transcriptional regulators such as Activa-
tor Protein-1 (AP-1) and the glucocorticoid receptor (GR).
Additional in silico analyses of whole genome ChIP sequen-
cing (ChIP-Seq) data using the UCSC Genome Browser
showed that RNA polymerase II and the c-MYC proto-
oncogene are bound to the conserved region preceding the
AKT1m exon in MCF7 breast cancer cells [17,18].
Human AKT1m transcripts are expressed and upregulated
in a subset of breast cancer cell lines and primary human
breast cancer specimens
The cloning of AKT1m mRNA transcripts from T47-D
breast cancer cells and the binding of RNA polymerase
II and c-MYC to conserved sequences immediately up-
stream of the start site of these novel mRNA variants en-
coding AKT1 are evidence for the expression of AKT1m
in neoplastic mammary epithelial cells. To verify the
presence of the transcripts and to determine the levels
of AKT1m mRNA expression, we performed a quantita-
tive RT-PCR assay across a panel of 41 human breast
epithelial cell lines. The panel consisted of three non-
tumorigenic lines (MCF-10A, MCF-10F, and MCF-12A)
and 38 selected cancer cell lines from ATCC that repre-
sent all major human breast cancer subtypes (Figure 5).
The relative expression of AKT1m was normalizedagainst GAPDH and the expression level of this mRNA
in MCF-10A cells. With the exception of MCF-12A
cells, the expression of AKT1m was significantly lower
in immortalized, untransformed mammary epithelial
cells (MCF-10A and MCF-10F) compared to the major-
ity of breast cancer cells. Nearly a quarter (24%) of the
38 breast cancer samples expressed AKT1m transcripts
at levels at least two-fold greater than all three non-
tumorigenic samples, and 33 of 38 lines (87%) exhibited
expression levels that were higher than both MCF-10A
and MCF-10F cells. Collectively, 29 of the 38 breast can-
cer cell lines displayed significantly greater AKT1m ex-
pression compared to MCF-10A control cells. Six lines
lacked statistical significance, and three breast cancer
cell lines exhibited lower expression. Similar to mouse
mammary tumors, there seems to be no obvious correl-
ation between AKT1m upregulation, hormone receptor
status, or breast cancer subtype.
Next, we verified the transcriptional activation of
AKT1m using quantitative RT-PCR on three primary hu-
man breast tissues and nine breast cancers, including
three ERα-positive, three HER2-positive/ERα-negative,
and three triple-negative specimens (Figure 6). We also
included additional samples from other organs into this
analysis (i.e., lung, liver, pancreas, and stomach) to assess
whether, similar to the expression profile that we ob-
served in mice, AKT1m expression is largely confined to
the mammary gland. While the AKT1m transcripts were
detectable in the normal human breast derived from re-
duction mammoplasties, there was only a marginal in-
crease in the transcriptional activation in ERα-positive
tumors. Unlike in genetically defined lesions of the
mouse mammary tumor models that exhibited elevated
levels of Akt1m in virtually all tumors, the expression of
the orthologous transcripts in human breast cancers were
more variable and therefore lacked statistical significance.
Figure 5 AKT1m transcripts are expressed and upregulated in a subset of human breast cancer cell lines. Quantitative real-time RT-PCR
analysis to assess the relative transcriptional activation of the AKT1m transcripts in a panel of three untransformed human breast epithelial cell
lines and 38 breast cancer cell lines that represent all major subtypes of this malignancy (i.e., ERα-positive, ErbB2-positive, and triple-negative).
Each sample was examined in triplicate and normalized to GAPDH expression. The expression of AKT1m in untransformed MCF-10A cells was set
to 1.0 and statistical analysis was performed for each cell line relative to the MCF-10A control; t test *P < 0.05, **P < 0.01.
Figure 6 Expression of AKT1m in normal breast tissues and selected breast cancer specimens. qRT-PCR analysis to determine the relative
expression of the AKT1m transcript variants in three primary human breast tissues and nine breast cancers from different patients, including three
ERα-positive as well as three Her2-positive/ERα-negative and three triple-negative specimens. Additional samples from other organs (i.e., lung, liver,
pancreas, and stomach) were included into this analysis to assess a possible widespread or tissue-specific expression of the AKT1m transcripts. Note
there was a clear elevation in the expression of AKT1m in the lung and stomach of two patients who were diagnosed with pneumonia and a GI stromal
tumor, respectively (circles). Each sample was examined in triplicate in the qPCR assay and normalized to GAPDH expression; bars represent SEM.
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breast cancer tissues exhibited a much greater expression
of AKT1m than all three normal breast specimens. The
data from this analysis on a limited number of primary
tumor samples of the three major breast cancer sub-
types essentially mirrors the quantitative RT-PCR re-
sults performed on a more extensive and well annotated
panel of breast cancer cell lines. Also, the expression of
AKT1m was lower in other healthy organs compared to
the normal mammary gland (Figure 6). Interestingly,
two samples in the lung and stomach showed a clear
elevation in the expression of AKT1m in patients that
were diagnosed with pneumonia and a gastric stromal
tumor. Collectively, the results from the analysis of nor-
mal and neoplastic cells and primary tissues indicate
that, unlike in mice, the transcriptional activation of
AKT1m is not entirely confined to the mammary gland.
However, the expression of AKT1m transcripts is sub-
stantially higher in a subset of breast cancer cell lines as
well as primary human breast cancers, and perhaps, in
malignancies or pathological conditions in organs other
than the mammary gland.
Discussion
The AKT serine-threonine protein kinases exhibit a
wide-spread expression pattern in virtually all human
cell types. They are activated downstream of various
growth factor receptors, in particular by receptor tyro-
sine kinases, through PI3 kinase-dependent mechanisms.
The three AKT isoforms (AKT1-3) control a number of
intracellular processes such as growth, proliferation, me-
tabolism, and cell survival [23-25]. Studies in single,
double, and triple knockout mice have shown that the
three AKT proteins can have redundant and non-
redundant functions in particular cell types [26-28].
Among the three AKT members, only AKT1 has been
shown to be crucial for normal mammary gland devel-
opment. During pregnancy and lactation, this kinase is
upregulated in the mammary epithelium where it con-
trols metabolic pathways that regulate milk synthesis
and the functional differentiation of the gland [27,29].
Immediately following the cessation of lactation and
weaning of the offspring, AKT1 mRNA and protein
levels decline rapidly to facilitate a swift remodeling of
the mammary epithelium [4,30]. A sustained expression
of hyperactive or wildtype AKT1 is entirely sufficient to
delay apoptosis and mammary gland involution [30-32].
The expression and functionality of AKT1 parallels
closely the biological functions of prolactin and its
downstream signaling mediators. We have demonstrated
previously that the activation of AKT1 as well as the
total levels of this kinase are dependent on the Janus
kinase 2 (JAK2) and active STAT5 [16]. More recently,we identified a novel role of JAK2/STAT5 signaling in
the transcriptional activation of the Akt1 gene in mice
[4]. Upon binding to the promoter of Akt1 in a growth
factor-dependent manner, STAT5 initiates the transcrip-
tion of a unique Akt1 mRNA from a distinct promoter,
which was only present in the mammary gland. Using
transgenic mice that express hyperactive STAT5 in a
ligand-regulatible manner, we demonstrated that gain-
of-function of this transcription factor mediates a sus-
tained upregulation of Akt1 in vivo [4]. Phenotypically
similar to females that overexpress AKT1, the prolonged
activation of STAT5 impaired postlactational remodeling
of the mammary gland. Collectively, the results of our
previous lines of investigation revealed a novel mechan-
ism by which the Akt1 gene can be transcriptionally reg-
ulated from an alternative promoter depending on the
developmental state and physiological needs.
Active STAT5 and AKT1 both mediate evasion from
apoptosis and self-sufficiency in growth signals, which
are hallmarks of cancer. In support of this notion it has
been observed that both signal transducers exhibit a
deregulated expression and activation in human breast
cancers. Moreover, it has been demonstrated that JAK2/
STAT5 signaling and AKT1 play essential roles during
mammary tumor initiation in various murine cancer
models [7,8,33-36]. Specifically, upregulation and activa-
tion of AKT1 is required to sustain a hypermetabolic
state (e.g., “Warburg effect”) that is a unique characteris-
tic of certain cancer cells [37,38]. As demonstrated in
this report, the majority of luminal- or basal-type mam-
mary tumors showed an increased expression of AKT1
on the protein level and a significant upregulation of the
Akt1m transcript. Similar to the regulation of AKT1 dur-
ing normal mammary gland development, cancer cells
are able to upregulate this serine-threonine kinase on
the transcriptional level to meet the specific metabolic
needs in the transformed state. Using in silico analysis,
we were able to identify the human ortholog of the mur-
ine Akt1m, but unlike in mice that only express a single
Akt1m mRNA, we cloned four new transcripts in human
cells that originated from a previously unidentified, alter-
native promoter. Since the ATG start codon is located
within the downstream exons (i.e., exons 2 or 3 depend-
ing on the specific transcript variants), it is evident that
all four newly identified mRNAs include the first coding
exon and therefore encode the full-length AKT1 kinase.
RT-PCR results using the AKT1m specific primer in the
5′UTR in combination with two reverse primers within
downstream coding exons confirmed a correct splicing
within the CDS of the AKT1 mRNA. The four new
AKT1m transcripts were initially cloned from prolactin-
responsive T47-D breast cancer cells, but the analyses of
a larger panel of breast cancer cells as well as primary
tumors show that expression of AKT1m is not restricted
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lower, the AKT1m transcript variants were also detect-
able in untransformed mammary epithelial cells and nor-
mal breast tissue specimens. This suggests that they are
not a result of aberrant splicing, which more frequently
occurs in transformed cells [39]. Another distinct char-
acteristic is the presence of AKT1m in other normal hu-
man tissues (i.e., lung, liver, pancreas, and stomach).
Although the expression in these organs was typically
lower compared to the breast, the Akt1m was not de-
tected at all in tissues other than the mammary gland in
mice using RT-PCR. The notion that the regulation of
the alternative AKT1m promoter might show some
species-specific differences is supported by the absence
of the STAT5 binding sites in the human locus. In mice,
we found two high-probability STAT5 binding sites up-
stream and immediately downstream of the Akt1m exon.
Using chromatin immunoprecipitation (ChIP) and quan-
titative PCR on lysates from cultured cells as well as
mammary gland tissues, we demonstrated that STAT5
binds to these particular recognition sites in a growth
factor-dependent manner to significantly enhance Akt1m
transcription [4]. Like the activation of milk protein gene
promoters, STAT5 seems to confer a tissue-specific ex-
pression profile of Akt1m in conjunction with other
transcription factors such as the glucocorticoid receptor
in the mouse [40]. The absence of STAT5 binding sites
might account for the lack of mammary gland specificity
in humans. However, there are multiple GR binding sites
present within the highly conserved orthologous region
in the human sequence immediately upstream of the
first exon of AKT1m. More importantly, the confirmed
presence of c-MYC on the conserved putative promoter
sequences immediately upstream of AKT1m using ChIP
might be indicative of a growth-factor controlled expres-
sion of AKT1 depending on metabolic needs. In support
of this notion, both AKT1 and c-MYC synergistically
promote metabolic reprograming and aerobic glycolysis
in cancer cells [37,38]. The identification of a novel pu-
tative promoter sequence in AKT1 that is conserved be-
tween humans and mice is an interesting finding, but
additional work is required to further pinpoint and con-
firm the functionality of the AKT1m promoter along
with the transcription factors that control its activation.
Regardless of the species-specific nuances in the regu-
lation of Akt1m, it is evident that the transcriptional
regulation of the Akt1 locus is more complex than previ-
ously thought. In mice as well as humans, the Akt1 gene
is transcriptionally upregulated in a subset of cancer
cells, and the growth factor-dependent activation activa-
tion of this locus occurs through at least two distinct
promoters. This is supported by our 5′RACE data and
published sequences in GenBank that the AKT1m-spe-
cific untranslated exon is absent in other known mRNAsequences that start at the originally identified promoter
located much further upstream [3]. The latter promoter
and associated non-coding exon are very GC-rich, and
attempts to generate primer sets to discriminate and to
quantify the contribution of the AKT1m transcripts to the
total pool of AKT1 mRNA messages have been unsuccess-
ful. Interestingly, besides the upregulation of AKT1m in a
subset of human breast cancers, elevated levels of these
transcript variants were also found in other diseased tis-
sues (i.e., pneumonia of the lung, and GI stromal tumor).
The qRT-PCR assay that we employed might be a simple,
yet sensitive, diagnostic tool to assess pathological changes
indicative of an altered metabolism that may correlate
with a transcriptional upregulation of AKT1.Conclusions
The collective results of this study suggest that, like in
mice, the expression of the AKT1 locus in humans is
controlled by at least two distinct promoters, suggesting
that the transcriptional activation of this gene is more
complex than previously thought. Four novel transcript
variants were identified in breast cancer cell lines that
are orthologous to the mouse Akt1m mRNA message.
All encode the full-length AKT1 serine threonine pro-
tein kinase, and these transcripts originate from a puta-
tive promoter sequence that is conserved between
humans and mice. All mammary cancers that developed
in diverse genetically engineered mouse models as well
as a subset of human breast cancer cell lines and pri-
mary breast cancers exhibited a much higher expression
of AKT1m. AKT1 is generally viewed as a persistently
active house-keeping gene, but the existence of an alter-
native promoter within this gene locus may provide a
mechanism by which the levels of AKT1 can be tempor-
ally and spatially regulated at particular physiological
states, such as cancer, where a heightened activity of this
kinase is required. Further studies will show whether tar-
geting specifically the expression of AKT1m is a suitable
strategy to downregulate AKT1 in breast cancer cells
without a complete ablation of the ubiquitously expressed
transcripts in normal tissues.
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